Minovia Therapeutics Announces FDA Clearance of Second IND Application, for a Phase II Clinical Trial of Lead Product MNV-201 in Pearson Syndrome

MNV-201 is Minovia’s second generation mitochondrial cell therapy product composed of autologous hematopoietic stem cells enriched with allogeneic mitochondria

Rare Pediatric Designation granted

MNV-201 is also being studied in a Phase Ib for low-risk Myelodysplastic Syndrome; Preliminary clinical data demonstrate safety and efficacy

HAIFA, Israel, April 03, 2025 (GLOBE NEWSWIRE) -- Minovia Therapeutics Ltd, a clinical stage biopharmaceutical company advancing mitochondrial therapies for primary and secondary mitochondrial diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its second Investigational New Drug (IND) application for MNV-201, an autologous hematopoietic stem cell product augmented with allogeneic mitochondria. The IND supports the initiation of a Phase II clinical trial of MNV-201 in pediatric patients with Pearson Syndrome, a primary mitochondrial disease.

Based on previous clinical experience from the 1st generation product, MNV-101 (autologous hematopoietic stem cell product augmented with syngeneic maternal mitochondria), Minovia designed this phase II study with change in growth (height SDS) as primary endpoint. According to the natural history study recently published by Dr. Rebecca Ganetzky from CHOP, all patients with Pearson Syndrome suffer from failure to thrive and do not respond to growth hormone. Natural history shows an annual reduction of 0.5 units in height SDS, while MNV-101 treated patients showed stabilization or improvement, with no decline of height SDS at the 6 and 12 month follow up time points in a comparable subset of patients. This change in growth correlated with an improved International Pediatric Mitochondrial Disease Scale (IPMDS), which measures how the patient feels and functions (R2=0.9; p=0.0036). Linear growth was also suggested as an objective and clinically meaningful endpoint for a pivotal trial in Pearson by the FDA in early interactions.

“The FDA’s clearance of our IND marks an important achievement for Minovia, allowing us to clinically evaluate our allogeneic mitochondrial cell therapy approach and proceed with the Phase II clinical program for this first-in-class allogeneic mitochondrial therapy for Pearson Syndrome patients,” said Natalie Yivgi Ohana, PhD, CEO of Minovia. “We are pleased to have safely dosed three Pearson patients enrolled in an ongoing study under the Israeli Ministry of Health. We look forward to treating additional patients under this IND, as well as to learning about the potential of MNV-201 to improve growth in this patient population.”

“We are pleased that our cumulative interactions with the FDA enabled alignment on requirements for the entire MNV-201 program, including preclinical, CMC, and clinical aspects,” said Noa Sher, PhD, CSO of Minovia. “Early clinical and regulatory experience with MNV-101 shaped the current program and enabled a successful IND submission.”

The Phase II clinical trial is an open-label, single dose study to evaluate the safety and efficacy of MNV-201 in pediatric subjects diagnosed with Pearson Syndrome. The trial will also enable assessment of efficacy in improving growth and quality of life. The study is expected to enroll three additional patients up to a total of 6 patients. For more information visit clinicaltirals.gov

About MNV-201
MNV-201 is an autologous hematopoietic stem cell product enriched with allogeneic mitochondria. MNV-201 aims to restore mitochondrial function in patient hematopoietic stem cells, resulting in improved differentiation and function. Preclinical research suggests the potential for safe dosing with low immunogenicity risk and scalable manufacturing to address the significant number of patients who are potentially eligible for MNV-201 therapy.

About Pearson Syndrome
Pearson Syndrome is a multisystem progressive pediatric mitochondrial disease caused by single large-scale mitochondrial deletions (SLSMDS) of mitochondrial DNA (mtDNA), with consequent defects in the mitochondrial respiratory chain function. Pearson Syndrome classically presents in the first year of life with bone marrow failure and exocrine pancreatic dysfunction. Patients have macrocytic sideroblastic anemia that is frequently transfusion-dependent and may be accompanied by thrombocytopenia and neutropenia. Pancreatic dysfunction occurs secondary to fibrosis and leads to chronic diarrhea, malabsorption, and failure to thrive. Pearson Syndrome is marked by accumulating organ system involvement and worsening disease: variable other organ involvement can occur, including renal tubulopathy, liver cholestasis and/or fibrosis, adrenal insufficiency, diabetes mellitus, cardiomegaly, and/or cardiac conduction defects. Pearson Syndrome is universally fatal and since there is no effective therapy, the diagnosis of Pearson Syndrome is one of the worst diagnoses that a caregiver must deliver to parents of an affected infant. MNV-201 aims to reduce disease-associated symptoms and the risk of disease progression and death, thereby improving both lifespan and quality of life.

About Minovia Therapeutics
Minovia Therapeutics Ltd. is a clinical stage biotechnology company advancing mitochondrial therapies for primary-genetic and age-related mitochondrial diseases. Minovia's clinical stage product candidate, MNV-201, is composed of mobilized peripheral blood, autologous CD34+ cells enriched with allogeneic, cryopreserved placental derived mitochondria, produced by Minovia's proprietary Mitochondrial Augmentation Technology (MAT). The enrichment of hematopoietic stem cells with healthy and functional mitochondria aims to restore stem cells function of patients suffering mitochondrial dysfunction, caused both by mtDNA mutations or deletions in pediatric patients suffering from primary mitochondrial diseases, or in adults with age-related diseases. MNV-201 is currently in clinical studies for pediatric patients with single-large scale mtDNA deletion syndromes (Pearson Syndrome and Kearn Sayre Syndrome) with five patients successfully dosed; and in Low Risk Myelodysplastic Syndrome. For more information, please visit www.minoviatx.com or follow the Company LinkedIn.

Contact Information: Natalie Yivgi Ohana, Co-Founder and CEO

Phone: +972-74-7039954

Email: info@minoviatx.com


Minovia Therapeutics Announces FDA Clearance of Second IND Application, for a Phase II Clinical Trial of Lead Product MNV-201 in Pearson Syndrome


THỦ THUẬT HAY

Hướng dẫn sửa đổi thông tin trên VssID đơn giản, nhanh chóng

Khi bạn muốn sửa đổi thông tin trên VssID, vậy thì đâu là cách? Đừng quá lo lắng, sẽ giúp bạn nhé!

Hướng dẫn chia sẻ tài khoản không lo mất mật khẩu như Facebook, Fshare, Youtube...

Nếu bạn muốn chia sẻ tài khoản cho bạn bè và người thân mà lại đang lo lắng bị lộ thông tin thậm chí mất tài khoản thì với hướng dẫn chia sẻ tài khoản không lo mất mật khẩu mà TCN giới thiệu sau đây, bạn sẽ hoàn toàn

Cách xuất mật khẩu đã lưu trên trình duyệt Chrome mà bạn nên dùng

Để đơn giản hóa quá trình đăng nhập, cũng như tránh việc người dùng tự quên mật khẩu của chính mình, Google Chrome được tích hợp sẵn tính năng tự động gợi ý người dùng lưu mật khẩu trên chính trình duyệt này. Những mật

Cách thay đổi thư mục tải về trên Samsung Internet cực kỳ đơn giản

Một số người dùng gặp khó khăn về tìm nơi lưu tài liệu, hình ảnh,... mà mình đã tải xuống trên Samsung Internet. Đây là cách thay đổi thư mục tải về trên Samsung Internet...

Hướng dẫn tra cứu điểm thi THPT Quốc gia 2018 nhanh nhất

Sau khi biết điểm thi, thí sinh được quyền làm đơn phúc khảo từ ngày 11/7 đến 20/7 tại nơi nộp hồ sơ đăng ký dự thi ban đầu, không hạn chế số môn phúc khảo. Cho dù đã có đáp án bài thi THPT Quốc gia 2018 của Bộ

ĐÁNH GIÁ NHANH

Galaxy Z Flip3 5G có gì đặc biệt để thuyết phục người dùng xuống tiền?

Giữa tháng 8 vừa qua Samsung đã trình làng smartphone màn hình gập Galaxy Z Flip3 5G với thiết kế vô cùng nhỏ gọn và tích hợp nhiều công nghệ hiện đại. Ngoài hai yếu tố trên, Galaxy Z Flip3 5G có gì đặc biệt để đốn tim

Trải nghiệm nhanh Acer Swift 3 2017, laptop đầu tiên trang bị CPU Intel thế hệ 8 tại Việt Nam

Vừa qua Intel đã chính thức giới thiệu dòng CPU Core i thế hệ thứ 8 cho laptop dưới tên gọi là Kaby Lake Refresh và rất nhanh sau đó Acer cũng đã giới thiệu phiên bản nâng cấp cho dòng Swift 3 của hãng trang bị chip xử

Thiết kế Huawei P20 Pro: Viền siêu mỏng nhưng vẫn giữ được nét truyền thống

Huawei P20 Pro được biết đến là chiếc điện thoại đầu tiên trên thế giới sở hữu 3 camera sau. Hiệu quả của 3 camera này nhanh chóng được kiểm chứng khi P20 Pro nhận được những số điểm “khổng lồ” từ trang đánh giá camera